Quick summary
Fibronectin peptides are bioactive fragments containing the RGD cell-adhesion motif and PHSRN synergy sequence from the extracellular matrix protein fibronectin. They are studied for wound healing acceleration, tissue engineering scaffolds, and implant surface coatings to improve osseointegration.
Overview
Fibronectin peptides are bioactive fragments derived from the large extracellular matrix glycoprotein fibronectin, primarily containing the RGD cell-adhesion motif and the synergy sequence PHSRN. They are studied for wound healing, tissue engineering, cell migration promotion, and as surface coatings for implantable biomaterials.
Mechanism of action
Fibronectin's primary integrin-binding motif, RGD (Arg-Gly-Asp), located on the type III10 fibronectin domain, engages α5β1, αvβ1, αvβ3, and αvβ5 integrins. A synergy site — PHSRN on the adjacent type III9 domain — cooperates with RGD for maximal α5β1-mediated adhesion and migration. Integrin engagement activates FAK, Src, and downstream MAPK/PI3K/Akt pathways, driving cell spreading, proliferation, and survival. In wound healing contexts, fibronectin peptides accelerate keratinocyte migration, promote fibroblast matrix remodeling, and support angiogenesis via integrin-VEGF receptor crosstalk.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| wound healing / surface coating | topical | 1–100 mcg/cm² | single or repeated application | Application method and concentration vary by formulation and wound type; research protocols define parameters |
| cell adhesion / tissue engineering | subcutaneous | 10–100 mcg | research use only |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Fibronectin's role in wound repair is well established: it is a primary component of the provisional wound matrix and provides the adhesive substrate for migrating keratinocytes and fibroblasts. Synthetic fibronectin peptides and fragments incorporating RGD and PHSRN have been tested in preclinical wound models with positive results for re-epithelialization. Fibronectin peptide coatings on implants reduce fibrous encapsulation and improve osseointegration. Clinical translation is ongoing; no fibronectin-derived peptide is FDA-approved as a standalone drug, though fibronectin is present in some wound care biologics.[1][2][3][4]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Fibronectin Peptides for synergistic effects.
Legal status
Fibronectin-derived peptides are used as research reagents and in experimental biomaterials. Not approved as standalone human therapeutics. Recombinant fibronectin fragments are available for research use.
Sourcing & access
Research compound
Fibronectin Peptides is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Fibronectin peptides are bioactive fragments derived from fibronectin, a large extracellular matrix glycoprotein. They primarily contain the RGD cell-adhesion motif and the PHSRN synergy sequence, which together mediate cell attachment, spreading, and migration.
The RGD motif on fibronectin's type III10 domain engages multiple integrins, while the PHSRN synergy site on the adjacent III9 domain cooperates for maximal adhesion. Integrin engagement activates FAK, Src, and downstream MAPK/PI3K/Akt pathways, driving cell spreading, proliferation, and wound repair.
In research contexts, fibronectin peptides show minimal side effects. Potential immunogenicity may occur with repeated systemic exposure. No fibronectin-derived peptide is FDA-approved as a standalone drug, though fibronectin is present in some wound care biologics.
Fibronectin peptide coatings on implants reduce fibrous encapsulation and improve osseointegration. In wound healing, they accelerate keratinocyte migration and promote fibroblast matrix remodeling. Synthetic fragments incorporating both RGD and PHSRN have shown positive results in preclinical wound models.
Research references
- Fibronectin-derived peptides promote cell adhesion and wound healingPubMed
- RGD and other functional sequences in fibronectin as cell-binding ligandsPubMed
- Fibronectin fragments and their role in tissue repair and inflammationPubMed
- Synthetic fibronectin-mimetic peptides in biomaterial scaffold designPubMed